An Italian court ruling has upheld the suspension of a government mandate to cut prices for medical devices, invalidating the program that was scheduled to go into effect in January. The court found that the price cuts were based on a faulty use of the national medical device classification system and used inaccurate price sampling. Italian health care authorities must now come up with a different formula for implementing cost controls that recognizes the varied and specialized characteristics of the medtech sector.
Suspension of Italian medtech price cuts upheld
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|